MindMaze Therapeutics Holding SA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Zach Henderson
- Full Time Employees
- 10
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Chemin de Roseneck 5 Geneva GE Switzerland 1202
- IPO Date
- Sep 19, 2011
- Website
- mindmazetherapeutics.com
- Similar Companies
- Business
- MindMaze Therapeutics Holding SA operates as a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company focused on digital neurotherapies for neurological diseases and brain disorders. The group develops and commercializes disease-modifying neurotherapeutics delivered through proprietary software and hardware, underpinned by an integrated brain technology platform that combines wearables, sensors, software, and telehealth capabilities to enable clinical and home-based care. Its product suite encompasses digital treatments and neurorehabilitation solutions designed for stroke, Parkinson’s disease, cognitive impairment, and aging-related neurological risk, with outcomes assessed through real-world evidence and health economic data. Founding year and headquarters MindMaze Therapeutics Holding SA traces its corporate evolution from its Relieff/ MindMaze lineage and operates with headquarters in Switzerland, maintaining operations and partnerships across Europe, the United States, and select global markets. Main products and services Digital neurotherapeutics platforms, at-home neurorehabilitation programs, telehealth-enabled clinical care pathways; software-driven brain therapy applications; sensor-integrated wearables and biosignal capture devices; patient monitoring and real-time data analytics; reimbursement-driven care models and health economics studies; strategic clinical collaborations and pharmaceutical development partnerships. Latest major company changes The company undergoes a strategic transition toward expanded U.S. and European market access, including growth initiatives in commercial deployment, reimbursement strategy advancement, and governance enhancements. Recent corporate updates include organizational restructuring to streamline operations, governance updates, and an emphasis on accelerating partnerships for digital neurotherapies and potential pharmaceutical collaboration, as reflected in 2025–2026 investor materials and corporate presentations. These moves accompany a broader push to broaden adoption of its digital neurotherapeutics platform, improve access within the U.S. provider ecosystem, and advance Europe-focused reimbursement and clinical coordination efforts. Industry context and business segments Industry: digital neurotherapeutics, neurotechnology, and biopharmaceutical assets; segments include digital brain rehabilitation software, at-home treatment programs, telehealth-enabled care delivery, and clinical/economic outcomes research. The company targets hospitals, clinics, and payer networks seeking innovative, cost-effective neurological care solutions. Geographic operations and subsidiaries Operations span Switzerland (headquarters), expanded activities in the United States and Europe, with ongoing discussions and collaborations intended to scale into additional international markets, supported by partnerships with provider groups, payers, and pharmaceutical partners. The corporate structure includes relationships stemming from its Relief Therapeutics lineage and potential restructuring into MindMaze Therapeutics Holding SA, with ongoing governance and alignment activities. Note Please refer to the company’s official communications and investor presentations for the most current details on product names, regulatory status, and specific partnerships as of 2026.
Company News
MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences
MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor
MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting
MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting
Edison Issues Report on MindMaze Therapeutics (MMTX)
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
Relief Therapeutics Publishes 2025 Half-Year Report
Relief Therapeutics Advances Publication of 2025 Half-Year Report
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
Relief Therapeutics Announces Results of Annual General Meeting
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial